Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have
different age-specific characteristics and definitions. Trials on surfactant for ARDS in children …

Adult respiratory distress syndrome (ARDS) frequently develops after near-drowning, smoke
inhalation, burns, blunt trauma to chest, and overwhelming sepsis. Surfactant depletion …

Ten newborn infants (795–1680 g) with severe respiratory distress syndrome (RDS) were
treated with the isolated phospholipid fraction of bovine or porcine surfactant, which was …

In recent years both natural and synthetic surfactants have been shown to be effective in
reducing mortality and morbidity in neonates with respiratory distress syndrome [1, 2, 4—24] …

Surfactant replacement therapy has been the mainstay of treatment for preterm infants with
respiratory distress syndrome for more than twenty years. For the most part, surfactant is …

Surfactant replacement therapy has been shown to be an effective and often life-saving
treatment for newborn infants with respiratory distress syndrome (RDS). Since the …

The lives of thousands premature babies have been saved along the last thirty years thanks
to the establishment and consolidation of pulmonary surfactant replacement therapies …

Exogenous surfactant replacement mixtures currently used for the prevention and treatment
of neonatal respiratory distress syndrome are either obtained from mammalian lungs or are …

We evaluated the effects of various ventilation strategies on the efficacy of exogenous
surfactant therapy in lung-injured adult rabbits. Lung injury was induced by repetitive whole …

The knowledge about surfactant biology is now deeper and recent research has allowed to
clarify its role in several human lung disorders. The balance between surfactant production …